Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population
POPULATION: Immigrants with LTBI.
METHODS: Participants were enrolled in a controlled, randomised clinical trial in Barcelona, Spain, from April 2001 to April 2005. Monthly follow-up was done to assess tolerance, side effects and adherence. Effectiveness was evaluated at 5 years.
RESULTS: In the 590 subjects enrolled, the rate of adherence was greater in the 3RH than in the 6H arm (72% vs. 52.4%, P = 0.001). No differences between study arms were observed with respect to hepatotoxicity or side effects. Variables associated with non-adherence were diagnosis by screening (OR 1.88, 95%CI 1.26–2.82, P = 0.001), illegal immigration status (OR 1.48, 95%CI 1.01–2.15, P = 0.03), unemployment (OR 1.91, 95%CI 1.28–2.85, P = 0.0008), illiteracy (OR 1.73, 95%CI 1.04–2.88, P = 0.02), lack of family support (OR 3.7, 95%CI 2.54–5.4, P = 0.001) and the 6-month treatment regimen (OR 2.45, 95%CI 1.68–3.57, P = 0.0001). None of the patients who completed either treatment developed tuberculosis.
CONCLUSIONS: The 3RH regimen facilitates adherence to LTBI treatment and offers a safe, well-tolerated and effective alternative.
Keywords: immigration; isoniazid; latent tuberculosis infection; randomised clinical trial; rifampicin
Document Type: Research Article
Affiliations: Unidad de Prevención y Control de la Tuberculosis de Barcelona, Servei d'Atenció Primària Suport al Diagnóstic i al Tractament, Institut Català de la Salut, Barcelona, Spain
Publication date: 01 March 2013
The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.
The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content